Interfractional Seminal Vesicle Motion Relative to the Prostate Gland for Image-guided Radiotherapy for Prostate Cancer with/without Androgen Deprivation Therapy: A Retrospective Cohort Study by Waki, Takahiro et al.
D ue to the advances in the biochemical detection of early prostate cancer by a simple laboratory 
test using prostate-specific antigen (PSA),  prostate can-
cer is now the most commonly diagnosed cancer among 
men in the U.S.,  and likely in Europe and Japan as well 
[1].  In recent years,  a marked increase in the number of 
patients with prostate cancer,  especially among the 
elderly,  has been noted [2].  Considering the increasing 
number of elderly patients with prostate cancer,  radio-
therapy (RT) has become one of the major treatment 
modalities.
It is well known that the volume of the otherwise 
untreated prostate gland shrinks during the course of 
androgen deprivation therapy (ADT).  After 3 months 
of ADT,  the volume of the prostate is reduced by 
20-50% [3-9],  and it continues to shrink up to 12 
months after the beginning of ADT,  albeit at a slower 
rate [10-15].  Therefore,  the irradiated volume needed 
during RT and the associated side effects could be 
Acta Med.  Okayama,  2017
Vol.  71,  No.  1,  pp.  31-39
CopyrightⒸ 2017 by Okayama University Medical School.
http ://escholarship.lib.okayama-u.ac.jp/amo/Original Article
Interfractional Seminal Vesicle Motion Relative to the Prostate Gland 
for Image-guided Radiotherapy for Prostate Cancer with/without  
Androgen Deprivation Therapy: A Retrospective Cohort Study
Takahiro Wakia＊,  Kuniaki Katsuib,  Toshiharu Mitsuhashic,  Takeshi Ogataa,   
Norihisa Katayamab,  Mitsuhiro Takemotod,  Yasutomo Nasue,  Hiromi Kumone,  and Susumu Kanazawaa
Departments of aRadiology,  and eUrology,  Okayama University Graduate School of Medicine,   
Dentistry and Pharmaceutical Sciences,  bDepartment of Radiology,  cCenter for Innovative Clinical Medicine,   
Okayama University Hospital,  Okayama 700-8558,  Japan,  dDepartment of Radiology,   
Japanese Red Cross Society Himeji Hospital,  Himeji,  Hyogo 670-8540 Japan
We investigated differences in seminal vesicle (SV) length and interfractional SV motion relative to the prostate 
gland in prostate cancer patients.  We compared 32 patients who received androgen deprivation therapy (ADT) 
before radiotherapy with 12 patients receiving radiotherapy alone at Okayama University Hospital in August 
2008-July 2011.  We examined the right and left SVs’ length and motion by computed tomography (CT) to 
determine the ADT’s effects and analyzed 347 CT scans in a multiple linear regression model.  The ADT 
patients’ SV length was significantly shorter than the non-ADT patients’.  The differences in right and left SV 
lengths between the ADT and non-ADT patients were 6.8 mm (95% CI 2.0-11.7 mm) and 7.2 mm (95% CI 3.1-
11.3 mm) respectively in an adjusted regression model.  SV motion did not differ between the ADT and non-
ADT patients in terms of interfractional motion of the SV tips and the SVs’ center relative to the prostate gland.  
The ADT patients had significantly shorter SVs compared to the non-ADT patients,  but no difference in SV 
motion was observed.  SV interfractional motion should thus be compensated using the same planning mar-
gins,  regardless of whether ADT is used.
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reduced; some authors have reported a reduction in the 
frequency of acute urinary and late gastrointestinal (GI) 
toxicities when ADT is used [16 , 17].
The development and clinical introduction of 
image-guided RT (IGRT) has resulted in more accurate 
treatments of prostate cancer [18],  and the risk of tox-
icity can thus be further reduced [19].  Many different 
imaging techniques can be used for prostate cancer,  
such as ultrasonography,  portal imaging,  megavolt 
computed tomography (CT),  in-room CT,  cone beam 
CT,  in-room magnetic resonance imaging (MRI),  and 
four-dimensional marker-based localization systems 
such as Calypso [18].  For prostate localization,  regis-
tration techniques can be based on the registration of 
implanted fiducial markers,  delineations,  or soft tissue 
[20-22].
For patients with intermediate- and high-risk pros-
tate cancer,  the seminal vesicles (SVs) are usually 
involved and are included in the clinical target volume 
[23].  Irradiation of the SVs has been shown to improve 
the overall and biochemical survival for these groups of 
patients [24].  However,  for prostate treatment that 
includes the SVs,  margin reduction is limited to a large 
extent by the mobility of the SVs,  as they may become 
deformed and/or move to a certain extent relative to the 
prostate gland.  Several reports showed interfractional 
motion characteristics of the SV relative to the prostate 
[20 , 25-27].  To our knowledge,  there has been no 
report on the differences in SV motion relative to the 
prostate gland during RT with or without ADT.  In 
addition,  although there are a few reports that the SV 
volume is reduced by ADT [28 , 29],  there has been no 
report on changes in SV length.  If the SV length can be 
shortened by ADT,  the mobility of the SV may also 
decrease,  thus potentially leading to reductions in the 
irradiated volume and side effects.
In the present retrospective analysis,  we investi-
gated differences in SV length and SV interfractional 
motion relative to the prostate gland in prostate cancer 
patients who have undergone RT with or without ADT.
Materials and Methods
Patients. The cases of 44 consecutive patients 
who met our inclusion criteria and who underwent 
3D-conformal RT or intensity-modulated radiotherapy 
(IMRT) at the Department of Radiology,  Okayama 
University Hospital between August 2008 and July 2011 
were retrospectively analyzed in this study.  The inclu-
sion criteria were: (1) no previous surgery or 
trans-urethral resection of the prostate,  (2) the avail-
ability of clinical information concerning ADT,  and (3) 
the presence of at least one calcified nodule in the pros-
tate gland.  All patients had biopsy-proven prostate 
carcinoma (T1c-3b) and underwent 3D-conformal RT 
or inversely planned “step-and-shoot” IMRT at 10 MeV 
photon energy.  The median total doses were 72 Gy in 
36 fractions.
Our study’s protocol was approved by the Ethics 
Committee and Institutional Review Board of Okayama 
University Hospital (ID no. 1738).  All patients were 
informed about the risks and benefits of treatment,  
agreed to have their cases analyzed,  and provided writ-
ten informed consent.
Androgen deprivation therapy. In this study,  we 
compared a group of 32 patients who underwent ADT 
to reduce the prostate size prior to RT with a group of 12 
patients who underwent RT alone.  The ADT group was 
treated primarily with a luteinizing hormone-releasing 
agonist plus an anti-androgen agent.  ADT was admin-
istered for a mean of 12.2 months (range 4.9-47.2 
months) before the RT.
Data acquisition. All of the patients underwent a 
simulation CT scan in the supine position for treatment 
planning 1-1.5hr after urination to ensure a distended 
bladder during simulation,  but no instructions were 
given on bowel emptying,  diet,  or laxative use.  The 
patients were immobilized using a HIP-FIX system 
(CIVCO Medical Solutions,  Orange City,  IA,  USA).
A pelvic simulation CT scan was performed without 
the use of oral or intravenous contrast material,  so that 
the planning scan could be directly compared with the 
non-contrast CT scans performed during the treatment 
course.  All patients were treated using a commercially 
available integrated CT-LINAC system (FOCAL unit,  
Toshiba Medical Systems,  Tokyo,  Japan),  which 
allowed for convenient CT imaging during the daily RT 
session with the patient immobilized in the treatment 
position.  Before each CT scan,  the patient was aligned 
using skin marks drawn during the simulation,  and the 
CT scans were always performed just before the daily 
treatments throughout the RT course.  All CT scans 
(including the planning CT scan) were performed with-
out contrast using 1-mm axial slices throughout the 
imaged area (Asteion Super 4 Edition,  Toshiba Medical 
Systems).  To minimize daily variations in bladder dis-
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tension,  the simulated conditions were maintained.
The acquired CT scans were imported into the 
Pinnacle3 treatment planning system (Philips Medical 
Systems,  Andover,  MA,  USA).  Seven to eight time 
points were chosen for each patient (planning CT and 
CT during treatment on days 5 , 10 , 15 , 20 , 25 , 30,  and 
35; total,  347 CT scans).  There was no primary time 
point of interest.  Among the total of 347 CT scans,  253 
CT scans were in the ADT group and 94 CT scans were 
in the non-ADT group.
The prostate gland,  bilateral SVs,  bladder,  and rec-
tum were manually contoured on the axial images for 
CT scans from the slice level of 1.5 cm above the SV tip 
to the slice level 1.5 cm below the prostate apex or anal 
verge.  Points of interest were set manually at the semi-
nal base and bilateral SV tips.  The center of the SV was 
determined as the center of 3 slices volume in the 
cranio-caudal direction in the middle of the SV [26].  
We calculated the average rectal and bladder cross-sec-
tional areas (CSAs) by dividing the total rectal and 
bladder volume by the rectal and bladder length.  We 
calculated the length of each right and left SV by sum-
ming the distance from the seminal base to the center of 
the SV and the distance from the center of the SV to the 
SV tip.
Organ motion. We measured the SV motion by 
first identifying a calcified nodule in the prostate gland 
on the planning CT.  The calcified nodule on the plan-
ning CT was then jointly registered to the calcified nod-
ule at the same position in the daily CT scan,  based on 
chamfer matching,  by obtaining translations in three 
dimensions.  For this study,  the registrations were lim-
ited to translations only,  because we simulated only the 
standard couch shift to correct the interfractional 
motions.
To quantify the positional shift for each point (bilat-
eral SV tips and bilateral SV centers) during treatment,  
we calculated the change in the position of each point 
relative to those on the planning CT in each direction 
(x-axis: lateral; y-axis: anterioposterior; z-axis: su-
perio-inferior).  We defined the anterior shifts,  inferior 
shifts,  and left displacements as positive values,  and we 
defined the posterior shifts,  superior shifts,  and right 
displacements as negative values.
Statistical analysis. We first examined the 
patients’ clinical characteristics based on their ADT 
status.  The variables were compared using an unpaired 
t-test for continuous variables and the chi-squared test 
for categorical variables.  We also examined the effect of 
ADT on the length and motion of the bilateral SVs.  The 
SV lengths were examined separately for the left and 
right sides.  The motions of the bilateral SV tips and 
bilateral SV centers were examined based on the x-axis 
(left),  y-axis (left),  z-axis (left),  and the x-axis (right),  
y-axis (right),  and z-axis (right).  The motion values 
were transformed to absolute values because we exam-
ined the magnitude of motion.  We then employed a 
multiple linear regression analysis to examine the effect 
of ADT.  After establishing a crude model,  we adjusted 
for potentially confounding factors,  as follows: bladder 
volume (per 10 cm3),  rectum volume (per 10 cm3),  
average bladder CSA (per 10 cm3),  average rectum CSA 
(per 10 cm3),  T factor (< 3a or > 3b),  and age (per 
decade).
We used generalized estimating equations (GEEs) to 
evaluate potential correlations between intra-patient 
measurements.  By using GEEs,  we investigate whether 
the results can be adapted to each patient.  We used a 
measurement as a unit of analysis in the GEE analysis.  
The GEE models were estimated using an exchangeable 
correlation matrix with robust standard errors [30],  and 
the correlation (ρ) in each model was calculated.  We 
estimated coefficients and 95% confidence intervals 
(CIs).  Statistical significance was set at p < 0.05 (two-
sided).  All analyses were conducted using the statistical 
software package Stata12 (StataCorp,  College Station,  
TX,  USA).
Results
Patient characteristic. The background compar-
isons were made based on the ADT status.  Significant 
findings were higher T stage,  lower bladder volume,  
and wider average rectum CSA in the ADT compared to 
the non-ADT group (Table 1).
SV length. Table 2 shows the results for the 
length of the right and left SVs.  The SV length was sig-
nificantly shorter in the patients who received ADT.  
There were no significant differences between the two 
patient groups for the other factors.  High correlations 
in the total series of patients were observed (ρ = 0.9/0.8 
in right/left SV lengths,  respectively).
Interfractional variability in SV position relative to 
the prostate gland. Tables 3 and 4 show the results of 
our analysis of the motion of the bilateral SV tips.  No 
significant differences were found between the ADT and 
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Table 1　 Patient characteristics, Okayama, Japan (2008-2011)
ADT (＋)1 n＝32 ADT (－)2 n＝12
p-value
n % n %
Measured 7 times  3  9.4  1  8.3 0.91
Measured 8 times 29 90.6 11 91.7
T factor
　　1c  1  3.1  5 41.7 ＜0.01
　　2a  4 12.5  4 33.3
　　2b  3  9.4  1  8.3
　　2c  7 21.9  2 16.7
　　3a 12 37.5  0  0.0
　　3b  5 15.6  0  0.0
Mean SD Mean SD p-value
Age (years)  71.1  6.2  67.8  6.9 0.13
Bladder volume (cm3) 124.4 46.5 138.1 51.6 0.02
Rectum volume (cm3)  51.4 20.8  48.1 20.8 0.20
Average bladder CSA (cm2)  29.9  9.3  30.4 10.4 0.72
Average rectum CSA (cm2) 　6.2  2.6 　5.3  2.2 ＜0.01
Radiotherapy duration (days)  53.3  2.1  53.8  2.4 0.56
ADT duration (months)  12.2  8.6 － －
ADT,  androgen deprivation therapy; SD,  standard deviation; CSA,  cross-sectional area.
1Patients who received androgen deprivation therapy prior to radiotherapy.  2Patients who received radiotherapy alone.
ADT group: 253 measurements (3×7＋29×8＝253).  Non-ADT group: 94 measurements (1×7＋11×8＝94).
Chi-squared tests were used for the analysis of the categorical variable.  Unpaired t-tests were used for the analysis of the continuous variable.
Table 2　 Regression analysis results for the diﬀerence in length of the right and left seminal vesicles,  Okayama,  Japan (2008-2011)
Right
Crude model Adjusted model
Estimate (mm) 95% CI Estimate (mm) 95% CI
ADT (non-ADT as reference) －6.1 －10.1 to －2.1＊ －6.8 －11.7 to －1.9＊
Bladder volume (per 10 cm3) 　0.1 －0.2 to 0.4　
Rectum volume (per 10 cm3) 　0.4 －0.8 to 1.6　
Average bladder CSA (per 10 cm2) －0.1 －1.4 to 1.3　
Average rectum CSA (per 10 cm2) －2.3 －14.1 to 9.5　
Severe T factor (＜3a/＞3b) 　0.7 －3.4 to 4.8　
Age (per decade) 　1.6 －1.3 to 4.4　
ρ (rho) 0.9 0.9
Left
Crude model Adjusted model
Estimate 95% CI Estimate 95% CI
ADT (non-ADT as reference) －5.7 －9.1 to －2.4＊ －7.2 －11.3 to －3.1＊
Bladder volume (per 10 cm3) 　0.0 －0.3 to 0.3　
Rectum volume (per 10 cm3) －0.1 －2.1 to 1.8　
Average bladder CSA (per 10 cm2) 　0.7 －0.7 to 2.1　
Average rectum CSA (per 10 cm2) 　3.7 －15.0 to 22.3　
Severe T factor (＜3a/＞3b) 　2.2 －1.2 to 5.6　
Age (per decade) 　0.3 －2.2 to 2.7　
ρ (rho) 0.8 0.8
ADT,  androgen deprivation therapy; CI,  conﬁdence interval; CSA,  cross-sectional area.
＊Statistically signiﬁcant (p＜0.05)
non-ADT groups in the motion of the right and left SV 
tips in any axis,  in either the crude or the adjusted 
model.  A not-very high correlation in the total series of 
patients was observed (ρ = 0.3-0.6/0.3-0.5 in right/left 
SV tips motion,  respectively).
Tables 5 and 6 show the results of the analysis of 
motion of the center of bilateral SVs.  No significant 
differences were found in the motion of the center of the 
right or left SVs in any axis in the crude model.  In the 
adjusted model,  the correlation between the rectum 
volume and the motion of the center of the right SV 
(y-axis) and the correlation between the rectum vol-
ume/average CSA and the motion of the center of the 
left SV (x-axis).  A not-very high correlation in the total 
series of patients was observed (ρ = 0.2-0.6/0.3-0.5 in the 
center of the right/left SV motions,  respectively).
Discussion
We analyzed the differences in the length of the SVs 
in patients who underwent RT with or without ADT 
using in-room CT,  and our findings revealed that the 
patients who underwent ADT had significantly shorter 
SVs compared to those who underwent ADT.  The 
shorter SVs can contribute to a decrease in irradiation 
volume,  especially for locally advanced prostate cancer 
patients,  and they may contribute to the reduction of 
harmful side effects caused by the irradiation.
To our knowledge,  there has been no report on the 
differences in SV motion relative to the prostate gland 
during RT with or without ADT.  We thus analyzed the 
differences in SV movement in patients who did or did 
not undergo ADT,  using in-room CT,  based on the 
hypothesis that shorter SVs have less mobility.  We 
found that SV mobility was not different between the 
ADT and non-ADT groups,  but the mobility was 
affected by the rectum change,  which is consistent with 
a previous report [27].
With regard to changes in the SVs,  to our knowl-
edge,  there have been only two reports stating that 
February 2017 Interfractional Seminal Vesicle Motion 35
Table 3　 Regression analysis results for the motion of the right seminal vesicle tip,  Okayama,  Japan (2008-2011)
Crude model Adjusted model
Estimate (mm) 95% CI Estimate (mm) 95% CI
X-axis
　ADT (non-ADT as reference) －1.4 －3.7 to 0.9 －1.7 －4.3 to 0.9
　Bladder volume (per 10 cm3) 　0.1 －0.1 to 0.4
　Rectum volume (per 10 cm3) －0.6 －2.2 to 1.0
　Average bladder CSA (per 10 cm2) －0.6 －1.7 to 0.6
　Average rectum CSA (per 10 cm2) 　6.6 －7.0 to 20.3
　Severe T factor (＜3a/＞3b) 　0.1 －0.8 to 1.0
　Age (per decade) 　0.3 －0.5 to 1.1
　ρ (rho) 0.6 　0.6
Y-axis
　ADT (non-ADT as reference) 　0.3 －2.3 to 2.8 　1.4 －0.7 to 3.6
　Bladder volume (per 10 cm3) 　0.0 －0.4 to 0.5
　Rectum volume (per 10 cm3) 　1.0 －0.7 to 2.7
　Average bladder CSA (per 10 cm2) －0.7 －2.6 to 1.2
　Average rectum CSA (per 10 cm2) －5.8 －19.9 to 8.4
　Severe T factor (＜3a/＞3b) －1.2 －2.9 to 0.5
　Age (per decade) －1.0 －2.9 to 0.9
　ρ (rho) 0.6 0.6
Z-axis
　ADT (non-ADT as reference) －0.3 －1.2 to 0.6 －0.3 －1.2 to 0.6
　Bladder volume (per 10 cm3) －0.1 －0.2 to 0.1
　Rectum volume (per 10 cm3) 　0.1 －0.6 to 0.7
　Average bladder CSA (per 10 cm2) 　0.1 －0.6 to 0.9
　Average rectum CSA (per 10 cm2) 　0.4 －5.0 to 5.9
　Severe T factor (＜3a/＞3b) 　0.0 －0.9 to 0.9
　Age (per decade) －0.3 －1.1 to 0.4
　ρ (rho) 0.3 0.3
ADT,  androgen deprivation therapy; CI,  conﬁdence interval; CSA,  cross-sectional area.
human SVs shrink with androgen ablation [28 , 29],  and 
there has been no report on the change in SV length.  
Terasaki et al.  showed that the decrease in the mean 
maximum horizontal area was 36% at 4 months and that 
it changed in parallel with the serum testosterone level 
[28].  Furuya et al.  showed through transrectal ultraso-
nography that the reduction in SV volume was 32.4% 
between the baseline values and 3-6 months after ADT 
[29].
Several reports have described the interfractional 
motion characteristics of the SVs relative to the pros-
tate.  Frank et al.  observed that the variability in SV 
displacement appeared to be greater than the variability 
in prostate displacement with respect to bony anatomy 
[27].  van der Wielen et al.  found that the deformation 
of the seminal vesicles relative to intraprostatic markers 
was significant (SD ≤ 3 mm).  Consequently,  the effect 
on treatment planning margins for prostate rotation 
corrections was small [20].
Jian et al.  reported that the SVs can move inde-
pendently from the prostate,  and the motion magni-
tude is larger in the anterioposterior direction.  A mini-
mum margin of 4.5 mm to the SV was recommended 
for IMRT with prostate-only guidance [25].  Smitsmans 
et al.  demonstrated that residual SV displacement that 
was not captured by the marker position is quite large 
(2-3 mm) in the anterioposterior direction in mark-
er-based IGRT.  Therefore,  correcting for rotations is 
not advisable when the SVs are part of the target vol-
ume,  and the margin design for SVs should take these 
uncertainties into account [26].
Several authors have already reported that ADT 
reduces the rate of harmful side effects by decreasing 
the irradiation volume needed for RT for prostate can-
cer patients [16 , 17].  In fact,  it is the reduction in pros-
tatic volume caused by ADT that enables the reduced 
irradiation volume.  The results of the present study 
clearly demonstrated that the patients who were treated 
with ADT had significantly shorter SVs compared to 
those who did not undergo ADT.  A high correlation 
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Table 4　 Regression analysis results for the motion of the left seminal vesicle tip,  Okayama,  Japan (2008-2011)
Crude model Adjusted model
Estimate (mm) 95% CI Estimate (mm) 95% CI
X-axis
　ADT (non-ADT as reference) －0.9 －2.3 to 0.4 －1.2 －2.7 to 0.4
　Bladder volume (per 10 cm3) 　0.1 －0.2 to 0.5
　Rectum volume (per 10 cm3) －0.7 －1.9 to 0.6
　Average bladder CSA (per 10 cm2) －0.5 －2.1 to 1.2
　Average rectum CSA (per 10 cm2) 　4.3 －7.4 to 16.0
　Severe T factor (＜3a/＞3b) 　2.6 －1.1 to 1.6
　Age (per decade) 　0.3 －0.6 to 1.3
　ρ (rho) 0.5 0.5
Y-axis
　ADT (non-ADT as reference) 　0.2 －1.4 to 1.9 　0.9 －0.7 to 2.5
　Bladder volume (per 10 cm3) 　0.1 －0.2 to 0.4
　Rectum volume (per 10 cm3) －0.1 －1.4 to 1.3
　Average bladder CSA (per 10 cm2) －0.6 －2.0 to 0.8
　Average rectum CSA (per 10 cm2) 　1.2 －10.0 to 12.4
　Severe T factor (＜3a/＞3b) －0.8 －2.2 to 0.6
　Age (per decade) －0.7 －1.9 to 0.5
　ρ (rho) 0.3 0.3
Z-axis
　ADT (non-ADT as reference) －0.1 －1.6 to 1.3 －0.4 －1.9 to 1.1
　Bladder volume (per 10 cm3) －0.1 －0.3 to 0.1
　Rectum volume (per 10 cm3) －0.2 －1.2 to 0.7
　Average bladder CSA (per 10 cm2) 　0.3 －0.7 to 1.3
　Average rectum CSA (per 10 cm2) 　3.2 －5.9 to 12.2
　Severe T factor (＜3a/＞3b) 　0.0 －1.4 to 1.4
　Age (per decade) －0.1 －1.2 to 1.1
　ρ (rho) 0.6 0.5
ADT,  androgen deprivation therapy; CI,  conﬁdence interval; CSA,  cross-sectional area.
regarding the bilateral SV length was observed,  which 
is not unexpected because the SV length should not 
change at each measurement point in each patient.  This 
shortening would lead to a reduced irradiation volume 
for RT in prostate cancer cases that include a seminal 
vesicle in the irradiation range,  such as in cases of 
locally advanced prostate cancer.
On the other hand,  according to previous reports,  it 
is necessary to consider the SV mobility relative to the 
prostate when setting the irradiation volume in IGRT 
[20 , 25-27].  We hypothesized that the SV movement 
would be reduced if the SV was shortened by ADT;  
however,  we observed no difference in SV movement,  
and the SV movement was affected further by factors 
such as the state of the rectum.  A not-very strong cor-
relation was observed regarding SV motion,  which 
indicated that the trend of SV motion was not constant 
in each patient.  We therefore recommend that the 
interfractional motion of SVs should be compensated 
for by using the same planning margins whether or not 
ADT is used when determining the irradiation volume.
One of the limitations of our study is that one or 
more other unmeasured/unknown confounders (i.e.,  
body mass index [BMI] and abdominal circumference 
[31]) between the ADT and non-ADT groups may have 
influenced the length and mobility of the SVs.  We did 
not collect the patients’ BMI or abdominal circumfer-
ence data,  due to a loss of data.  Another limitation is 
that the SV length and extent of motion were measured 
based on CT images.  Studies based on MRI in which 
the anatomic structure contrast is high are more precise.  
In addition,  the registrations were performed using a 
calcified nodule in the prostate gland,  likely by employ-
ing implanted fiducial markers; however,  the registra-
tions were limited to translations only because we sim-
ulated only the standard couch shift to correct 
interfractional motions.  With this method,  the defor-
mation and rotation of the prostate during daily treat-
ment is not considered.  The analyzed data were taken 
from patients who visited the university hospital,  and 
February 2017 Interfractional Seminal Vesicle Motion 37
Table 5　 Regression analysis results for the motion of the center of the right seminal vesicle,  Okayama,  Japan (2008-2011)
Crude model Adjusted model
Estimate (mm) 95% CI Estimate (mm) 95% CI
X-axis
　ADT (non-ADT as reference) －0.1 －0.9 to 0.6 －0.6 －1.4 to 0.2　
　Bladder volume (per 10 cm3) 　0.0 －0.1 to 0.1　
　Rectum volume (per 10 cm3) －0.3 －0.7 to 0.1　
　Average bladder CSA (per 10 cm2) 　0.0 －0.8 to 0.7　
　Average rectum CSA (per 10 cm2) 　3.0 －0.7 to 6.7　
　Severe T factor (＜3a/＞3b) 　0.3 －0.5 to 1.1　
　Age (per decade) 　0.5 0.0 to 1.0　
　ρ (rho) 0.5 0.5
Y-axis
　ADT (non-ADT as reference) －0.1 －2.1 to 2.0 　0.4 －1.4 to 2.2　
　Bladder volume (per 10 cm3) －0.1 －0.3 to 0.2　
　Rectum volume (per 10 cm3) 　1.2 0.1 to 2.2＊
　Average bladder CSA (per 10 cm2) 　0.1 －1.0 to 1.2　
　Average rectum CSA (per 10 cm2) －6.6 －15.9 to 2.7　
　Severe T factor (＜3a/＞3b) －0.5 －1.8 to 0.9　
　Age (per decade) －0.4 －2.0 to 1.2　
　ρ (rho) 0.6 0.6
Z-axis
　ADT (non-ADT as reference) －0.4 －0.9 to 0.1 －0.5 －1.0 to 0.0　
　Bladder volume (per 10 cm3) 　0.0 －0.1 to 0.0　
　Rectum volume (per 10 cm3) 　0.2 －0.1 to 0.6　
　Average bladder CSA (per 10 cm2) 　0.1 －0.2 to 0.5　
　Average rectum CSA (per 10 cm2) －1.7 －4.3 to 1.0　
　Severe T factor (＜3a/＞3b) 　0.2 －0.2 to 0.6　
　Age (per decade) －0.1 －0.5 to 0.2　
　ρ (rho) 0.2 0.2
ADT,  androgen deprivation therapy; CI,  conﬁdence interval; CSA,  cross-sectional area.
thus the possibility remains that the backgrounds of the 
patients were different from those of the patients who 
visited general hospitals.  It may thus be questionable to 
interpret our results as generalized.  These limitations 
should be addressed in future studies.  It is difficult to 
perform a randomized controlled study from the ethical 
point of view,  because ADT reduces the rate of harmful 
side effects for prostate cancer patients.  A propensity 
score analysis in which the confounding factors evalu-
ated in this study,  BMI,  and abdominal circumference 
are well adjusted should thus be performed.
In conclusion,  the patients who underwent ADT 
had significantly shorter SVs compared to the patients 
who did not undergo ADT.  No differences in SV move-
ment were observed between these groups.  Compensa-
tion for the interfractional motion of SVs should thus 
use the same planning margins whether or not ADT is 
used with RT.
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